Category: Board

Applications

Inobrodib is currently being evaluated for safety and efficacy in different multiple myeloma patient populations

Multiple Myeloma

Multiple myeloma (MM) and other hematological malignancies are regulated in part by p300/CBP.

Other Potential Applications

Inobrodib may have therapeutic utility in other p300/CBP-regulated cancers including acute myeloid leukaemia (AML), lymphomas, solid tumors and targeted tumors with specific genetic mutations.

About CellCentric

CellCentric is a clinical-stage biopharmaceutical company focused on the development of a first-in-class oral p300/CBP inhibitor to treat multiple myeloma and other cancer types.

Quick Links

About us
Inobrodib
Clinical trials
Publications
Our story

About us
Inobrodib
Clinical trials
Publications
Our story

Our team
Press releases
News
Contact
Expanded Access Policy
Privacy Policy

Our team
Press releases
News
Contact
Expanded Access Policy
Privacy Policy

Follow us and stay up to date with our latest news, events and scientific posters.

Icon-x Linkedin-in

Main Menu

About us
Inobrodib
News
- Press releases
- Publications
Contact us

Follow us on LinkedIn